Behçet's disease and etanercept: Eighty weeks of experience

European Journal of Inflammation

Volumn 7, Issue 2, 2009, Pages 117-120

  Kroegler, B ^a   Di Muzio, G ^a   Giovannangeli, F ^a   De Mattia, M ^a   Perricone, C ^a   Perricone, Roberto ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Anti TNF; Beh et's disease; Enbrel; Etanercept

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; HEPARIN; HYDROXYCHLOROQUINE; PREDNISONE;

ADULT; ARTHRITIS; ARTICLE; BEHCET DISEASE; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; FEMALE; GENITAL ULCER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC OPTIC NEUROPATHY; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; REMISSION; VISUAL ACUITY;

EID: 69549127767     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727x0900700208     Document Type: Article

References (20)

1. Yamashita N. Hyperreactivity of neutrophils and abnormal T-cell Homeostasis: a new insight for pathogenesis of Behçet's disease. Int Rev Immunol 1997; 14: 11-20. (Pubitemid 27185411)
2. Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease: soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997; 24:128-132 (Pubitemid 27059870)
3. Evereklioglu C, Er H, Turkoz Y, et al. Serum levels of TNF-α, sIL-2R, IL-6 and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm 2002; 11:87-93. (Pubitemid 34526411)
4. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab. Rheumatology Oxford 2001; 40:473-474 (Pubitemid 32409564)
5. Goossens PH, Verburg RJ, Breedveld FC. Remission of Behcet's syndrome with tumor necrosis factor alpha blocking therapy. Ann Rheum Dis 2001; 60:637.
6. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001; 358:295-296 (Pubitemid 32738970)
7. Triolo G, Vadala M, Accardo-Palumbo A, et al. Anti-tumor necrosis factor monoclonal antibody treatment for ocular Behcet's disease. Ann Rheum Dis 2002; 61:560-561 (Pubitemid 34539106)
8. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behcet's syndrome with chimeric tumor necrosis factor alpha antibody. Gut 2001; 49:725-728 (Pubitemid 32989213)
9. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology 2001; 120:995-999 (Pubitemid 32193197)
10. Yamashita N, Kaneoka H, Kaneko S, et al. Role of the γδ T lymphocytes in the development of Behçet's disease. Clin Exp Immunol 1997; 107:241-247
11. Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005; 89:533-536
12. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet disease with refractory uveoretinitis. J Rheumatol 2004; 31:1362-1368 (Pubitemid 38879203)
13. Sarwar H, McGrath Jr H, Espinoza LR. Successful treatment of long-standing Neuro-Behçet's disease with infliximab. J Rheumatol 2005; 32:181-183 (Pubitemid 40092611)
14. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of Etanercept in Behçet's disease: a double blind, placebo controlled study. J Rhematol 2005; 32:98-105. (Pubitemid 40092599)
15. Scheinberg MA. Treatment of recurrent oral aphtous ulcers with Etanercept. Clin Exp Rheumatol 2002; 20:733-734 (Pubitemid 35243794)
16. Elezoglou A, Kafasi N, Kaklamanis PH, Theodossiadis PG, Kapsimali V, Choremi E, Vaiopoulos G, Sfikakis PP. Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease. Clin Exp Rheumatol 2007; 25:S65-9.
17. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005; 52:2192-2201 (Pubitemid 40994342)
18. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301:418-426 (Pubitemid 34429950)
19. Zou JX, Braun J, Sieper J. Immunological basis for the use of TNF alpha-blocking agents in ankylosing spondylitis and immunological changes during treatment. Clin Exp Rheumatol 2002; 20:S34-7. (Pubitemid 35189999)
20. Chapman PT, Yarwood H, Harrison AA, et al. Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the role of tumor necrosis factor alpha and interleukin 1. Arthritis Rheum 1997; 128:443-450 (Pubitemid 27200014)